High overall response rate: 76.6% of patients in the pivotal cohort achieved CR/Cri following treatment with obe-cel with a median follow-up of 20.3 monthsLow incidence of immune-related toxicity: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback